Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PV-001 in Healthy Women
NCT07081334Phase 1Completed
- Sponsor
- PosVax
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Hydrogel Systems, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Vascugel in human papillomavirus infection (2 arms), sponsored by PosVax. Primary endpoint: Safety assessment. Started Aug 2022; status: completed.
02
Drugs
Vascugel
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07081334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081334.